Bioretec Announces Major Rights Issue for EUR 14.8 Million to Strengthen Capital Base

The Board of Directors of Bioretec Ltd has officially resolved to initiate a rights issue aimed at raising approximately EUR 14.8 million. This decision, announced on March 27, 2026, aims to provide existing shareholders the opportunity to subscribe to new shares at a preferential price, solidifying the company’s financial foundation in preparation for future growth.

Details of the Offering

The rights issue entails offering shareholders up to 1,477,828,416 new shares at a subscription price of EUR 0.01 per share, maintaining the proportionate distribution based on existing share ownership. The objective of this capital influx is to enhance Bioretec’s capital base and finance resources, ultimately supporting its strategic initiatives outlined in the company release from December 16, 2025.

Bioretec anticipates that these funds will primarily be utilized to scale up the commercialization efforts of its cutting-edge products, including the RemeOs product line, particularly in the United States. Furthermore, the proceeds will enable the continuation of the development pipeline, the launch of three new products within the next eighteen months, and improvements in operational and production capabilities.

Financial Structure and Expectations

Bioretec is targeting to raise at least EUR 5 million through this offering, backed by a commitment from Stephen Industries Inc Oy, which holds significant shares in the company. If the rights issue succeeds in raising the full EUR 14.8 million, the company believes it will secure sufficient working capital to execute its strategic plans until late 2027.

Current shareholders have a preferential right to purchase the new shares based on their existing holdings as recorded on the specified record date, March 31, 2026. Subscription rights will be allocated at a rate of one per existing share, enabling robust shareholder participation in this growth endeavor.

The new subscription period will commence on April 7, 2026, closing on April 21, 2026. Any unclaimed subscription rights at the end of this period will be rendered void. Additionally, trading for subscription rights will occur on the Nasdaq First North Growth Market in Finland, allowing for expanded liquidity and engagement from shareholders.

Management Commitment and Market Positioning

The chair of Bioretec’s Board, Kustaa Poutiainen, emphasized the commitment of the largest shareholder and the confidence in expanding their footprint in significant markets, such as the U.S. He highlighted the achievements in regulatory milestones and the company’s focused strategy for commercialization.

CEO Sarah van Hellenberg Hubar-Fisher also remarked on the transformative journey Bioretec has been on, indicating that the past year has been pivotal in reconfiguring the company’s framework for future growth. She asserted that now is the ideal time to capitalize on their advantageous market position, particularly with existing Breakthrough Device Designations and favorable payment statuses for their innovative products.

Conclusion

As Bioretec prepares to embark on this substantial rights issue, the corporate landscape is poised for potential shifts. Engaging shareholders in this capital increase not only fortifies the company’s financial standing but also signals an aggressive intention to harness growth opportunities within the orthopedic device market. The upcoming months will be crucial in determining the breadth of participation and the impact of this financial maneuver on Bioretec’s strategic ambitions. With a clear focus on optimizing value for shareholders, Bioretec continues its march toward redefining orthopedic care through innovative, absorbable technologies.

For further updates and participation details about the rights issue, shareholders and stakeholders are encouraged to keep an eye on Bioretec's official channels.